Straits Times Index
3,187.86 +33.17 (+1.05%) Nikkei
38,050.63 +88.83 (+0.23%) Hang Seng
16,410.97 +159.13 (+0.98%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,616.14 -2,298.81 (-3.60%) CMC Crypto 200
885.54 0.00 (0.00%)
UroGen Pharma Ltd. (0XOD.L)
| Previous close | 14.09 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 457 |
| Market cap | 2.081M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.05 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
PRINCETON, N.J., April 17, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.
Business WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J., April 15, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Simply Wall St.UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
Key Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the...
